What Else Can Tirzepatide Treat? Beyond Weight Loss and Diabetes

Tirzepatide is the medicine sold as Mounjaro and Zepbound. It is a once-weekly injection that switches on two gut hormone receptors, GIP and GLP-1, rather than the one that semaglutide (Ozempic, Wegovy) targets. That second receptor is part of why it produces more weight loss than semaglutide in a head-to-head trial, and part of why researchers keep testing it in conditions that have nothing obvious to do with blood sugar.

This page is a map of that research. It starts with what tirzepatide is actually approved for, then walks down the evidence ladder from “large randomized trial” to “interesting database finding that may not survive.” Nothing here is medical advice, and no dose is recommended. If a use below applies to you, it is a conversation for a healthcare provider, not a decision to make from a web page.

What is tirzepatide approved for right now?

Checked directly against the FDA prescribing information on September 14, 2026, there are four approved uses across two brands [1][2].

Mounjaro (tirzepatide) is approved:

• as an addition to diet and exercise to improve blood sugar control in adults and children 10 years and older with type 2 diabetes
• to lower the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk for those events [16]

Zepbound (tirzepatide) is approved:

• to reduce excess body weight and maintain that reduction long term in adults with obesity, or with overweight plus at least one weight-related condition
• to treat moderate-to-severe obstructive sleep apnea in adults with obesity

That is the entire list. There is no approved use for heart failure, kidney disease, fatty liver, polycystic ovary syndrome, osteoarthritis, addiction or anything cognitive.

One more thing worth pinning down, because it trips people up constantly: Mounjaro and Zepbound contain the same molecule. In the United States they carry different labels and are usually treated differently by insurance. In the United Kingdom, “Mounjaro” is also the weight-loss brand — so a UK article about Mounjaro for weight loss is not describing the US Mounjaro label.

What is the strongest non-weight evidence?

Three areas stand out, and they are not the ones that get the most social media attention.

Obstructive sleep apnea. This is the only non-weight, non-diabetes condition tirzepatide is approved for, and the trial behind it is convincing. SURMOUNT-OSA ran two parallel studies in 469 adults with moderate-to-severe sleep apnea and obesity, one in people using a CPAP machine and one in people who were not. After 52 weeks, breathing interruptions per hour of sleep — the apnea-hypopnea index — had fallen by 25.3 events in the no-CPAP group and 29.3 in the CPAP group, against about 5 on placebo. Up to 50.2 percent of treated participants reached a level of disease at which the label notes CPAP may no longer be recommended [3]. The FDA approved Zepbound for this use on December 20, 2024, making it the first medication ever approved for sleep apnea.

Preventing type 2 diabetes. The three-year arm of the SURMOUNT-1 trial followed 1,032 adults who had obesity and prediabetes. Over 176 weeks, 1.3 percent of those on tirzepatide were diagnosed with type 2 diabetes, against 13.3 percent on placebo — a 94 percent reduction, with nine people needing treatment to prevent one case [6]. That is a striking number. The equally important number sits 17 weeks later: after everyone came off the drug, weight, blood sugar and blood pressure all moved back toward where they started. This looks like a treatment you stay on, not a course you finish.

Heart failure with preserved ejection fraction. The SUMMIT trial randomized 731 adults with this kind of heart failure plus obesity. Cardiovascular death or a worsening heart failure event happened to 9.9 percent on tirzepatide versus 15.3 percent on placebo, and symptom and walking-distance scores improved [4]. This is covered in depth in our SUMMIT explainer, including why a positive trial did not produce an approved indication.

Does tirzepatide protect the heart and kidneys?

Partly, and the detail matters.

SURPASS-CVOT is the largest tirzepatide trial ever run: 13,299 adults with type 2 diabetes and existing heart disease, followed for a median four years. Unusually, it had no placebo group. Researchers judged it unethical to leave this population untreated, so they compared tirzepatide against dulaglutide (Trulicity), a drug already shown to reduce cardiovascular events. Over four years, the combined rate of cardiovascular death, heart attack or stroke was 12.2 percent on tirzepatide and 13.1 percent on dulaglutide. That met the statistical bar for being no worse, but not the bar for being better. Death from any cause was 16 percent lower on tirzepatide, a secondary result the authors flagged as exploratory [5].

That trial is what the August 2026 Mounjaro cardiovascular indication rests on [16]. Note what it does not cover: it applies to people who already have type 2 diabetes and high cardiovascular risk. It does not apply to Zepbound, and it says nothing about people without diabetes.

The question of whether tirzepatide prevents heart attacks in people who have obesity but not diabetes is what SURMOUNT-MMO is designed to answer. It enrolled 15,374 adults aged 40 and up with a BMI of at least 27 and either existing heart disease or multiple risk factors, and it is the first incretin outcome trial to include people who have not yet developed cardiovascular disease [14]. Completion is estimated for October 2027. Until then, nobody knows.

On kidneys, tirzepatide slowed the decline in kidney filtration compared with insulin in a post hoc analysis of an earlier trial, and a separate analysis using cystatin C confirmed that was not just an artifact of losing muscle. But semaglutide has an approved kidney indication and tirzepatide does not. Tirzepatide’s own kidney trial, TREASURE-CKD, is a 140-person phase 2 study measuring fat and oxygen levels in the kidney on MRI — a mechanism study, not an outcomes study.

Can tirzepatide treat fatty liver disease?

The phase 2 result was strong. In 190 adults with biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis) and moderate-to-severe scarring, 44, 56 and 62 percent of those on the three tirzepatide doses had their MASH resolve without worsening fibrosis at 52 weeks, against 10 percent on placebo [7]. Roughly half improved their fibrosis by at least one stage.

So why is there no approval? Because that was a phase 2 trial in 190 people, and the fibrosis result was not formally tested with the statistical adjustments that would be needed to make a claim. Semaglutide is the drug that carries the FDA accelerated approval for MASH, granted in August 2025.

Lilly’s phase 3 liver program took an unusual route. SYNERGY-OUTCOMES skips the biopsy endpoint that other MASH programs use to get accelerated approval, and instead runs an event-driven trial of tirzepatide and retatrutide against placebo in 4,500 adults, looking for hard outcomes like progression to cirrhosis, liver transplant or death [15]. It started in October 2025 and is scheduled to run about 224 weeks. Nothing will be known until roughly 2030.

Does tirzepatide help with alcohol or other addictions?

This is the area where the gap between the headlines and the evidence is widest, so it is worth being precise.

No randomized trial of tirzepatide for alcohol use disorder exists. The three randomized alcohol trials in this field used semaglutide or exenatide. What tirzepatide has is two other kinds of evidence.

First, database studies. A 2025 target trial emulation using records from more than 120 million US patients found that adults with type 2 diabetes starting tirzepatide had a 53 percent lower rate of a first alcohol use disorder diagnosis over 18 months than matched people on a different diabetes drug — the largest reduction among the four incretin drugs tested [10]. In the same analysis, the death rate was 72 percent lower in the tirzepatide group, which is not a plausible drug effect and tells you these comparisons carry real confounding.

Second, animal work. A 2026 study in eBioMedicine found tirzepatide reduced alcohol reward, voluntary drinking, binge drinking and relapse-like drinking in rats of both sexes, without tolerance developing.

Randomized trials are now starting. A four-site phase 2 trial is testing tirzepatide for smoking cessation in 300 adults who smoke, and another phase 2 trial is testing it added to buprenorphine in 310 adults with opioid use disorder. Neither has results.

What about the brain — dementia, cognition and food noise?

Several large database studies report lower dementia rates among tirzepatide users. A January 2026 analysis found tirzepatide associated with lower two-year dementia risk than semaglutide (hazard ratio 0.69) and than a different class of diabetes drugs (0.66), and used an unrelated condition as a check to see whether the whole thing was just an artifact of who gets prescribed what [12]. Another study reported relative risk reductions so large — an 88 percent lower rate of mild cognitive impairment — that the authors themselves asked readers to treat them descriptively.

Two things should temper enthusiasm. Dementia diagnoses in records are often late and incomplete. And the one large, well-run randomized program in this space, semaglutide’s EVOKE trials in early Alzheimer’s disease, missed its primary endpoint.

A different brain question got a striking answer in late 2025. Researchers at Penn recorded electrical activity directly inside the nucleus accumbens — a reward hub — of a woman taking tirzepatide. At full dose, her food preoccupation and the brain signal that precedes it went silent. Then, around month five, both came back, with seven severe episodes a month. It is one patient with an implanted device, so it proves nothing. But it is the first direct physiological hint that the quieting of “food noise” may not last.

Does tirzepatide affect cancer risk?

Two things are true at once and both belong in the answer.

Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rats, with human relevance undetermined, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome [1].

At the same time, a June 2026 study in Annals of Oncology followed 229,467 US adults who had obesity but not diabetes and compared people prescribed a GLP-1 drug against people counseled on diet and exercise. Over a median two years, obesity-associated cancers were 41 percent less common among drug users. Endometrial cancer fell 58 percent, and the reduction among men approached 70 percent. The authors reported the largest reduction among tirzepatide users specifically — and also that no reduction was seen among Black patients [11].

Two years is far too short a window to judge cancer incidence, and people in active medical care get screened more than people given diet advice. The senior author put it plainly: cancer risk reduction should not yet be a stand-alone reason to prescribe.

What else is being studied?

Briefly, with the honest evidence level attached:

• Polycystic ovary syndrome. One 60-person open-label randomized trial and a large real-world weight cohort. No phase 3 has reported. Covered in our PCOS article.
• Knee osteoarthritis. No dedicated tirzepatide trial has reported. A post hoc analysis found people with osteoarthritis in the SURMOUNT-1 trial lost 16 to 22 percent of their weight and gained physical function. A phase 4 trial testing whether tirzepatide keeps people off the knee replacement waiting list finishes in 2027.
• Type 1 diabetes. One 24-person, 12-week randomized trial found 8.7 kg more weight loss than placebo and a 35 percent reduction in insulin needs. A 2026 systematic review rated the certainty of evidence low to very low. A phase 3 trial is enrolling.
• Psoriasis and hidradenitis suppurativa. Small uncontrolled studies. A 20-person open-label study reported an 80 percent response rate in hidradenitis suppurativa; there was no control group.
• Idiopathic intracranial hypertension. Database signals suggesting less papilledema and vision loss, plus a randomized trial at Duke now recruiting.
• Binge eating disorder. A phase 2 trial at Johns Hopkins is comparing tirzepatide against placebo and against lisdexamfetamine, the only approved drug for the condition. No results until at least late 2027.
• Gout, bone, breathing, atrial fibrillation, peripheral artery disease, lipedema, low testosterone. All observational, small, or both. Several of the reported effect sizes are large enough to be implausible, which usually means the comparison groups differed in ways the analysis could not fix.

Is tirzepatide better than semaglutide?

For weight, the only head-to-head randomized trial gives a clear answer. SURMOUNT-5 randomized 751 adults with obesity and without diabetes to the maximum tolerated dose of each drug for 72 weeks. Weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide, and nearly twice as many people lost at least 25 percent of their body weight [8].

For anything else, the question is badly framed. Semaglutide has approved indications for cardiovascular risk reduction, chronic kidney disease and fatty liver that tirzepatide does not. Tirzepatide has a sleep apnea indication that semaglutide does not. The right drug depends on what problem you are trying to solve, what your insurance covers, and what you can tolerate — which is exactly the conversation to have with a prescriber.

The bottom line

Tirzepatide’s approved footprint is narrow: blood sugar and cardiovascular risk in type 2 diabetes under the Mounjaro label, weight and sleep apnea under the Zepbound label. Everything else people talk about falls into three buckets — a positive trial that did not become an indication (heart failure), a promising early trial waiting on a bigger one (fatty liver, PCOS, type 1 diabetes), or a database signal that may or may not be real (dementia, addiction, cancer, atrial fibrillation).

The single most useful mental filter: obesity makes a very long list of conditions worse, so any drug producing 20 percent weight loss will improve many of them. Whether tirzepatide does anything extra beyond that, through its receptors rather than through the scale, is still an open scientific question in almost every area on this page.

Sources

1. ZEPBOUND (tirzepatide) injection prescribing information — US Food and Drug Administration, 2026
2. MOUNJARO (tirzepatide) injection prescribing information, supplements 044/045 — US Food and Drug Administration, August 2026
3. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity — New England Journal of Medicine, June 2024
4. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity — New England Journal of Medicine, November 2024
5. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes — New England Journal of Medicine, December 2025
6. Tirzepatide for Obesity Treatment and Diabetes Prevention — New England Journal of Medicine, November 2024
7. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis — New England Journal of Medicine, June 2024
8. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — New England Journal of Medicine, 2025
9. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS) — The Lancet, September 2025
10. Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders — Diabetes, Obesity and Metabolism, October 2025
11. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults — Annals of Oncology, June 2026
12. Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia — Diabetes Research and Clinical Practice, January 2026
13. Lilly Withdraws Tirzepatide Application to FDA for Heart Failure — ConscienHealth, May 2025
14. SURMOUNT-MMO registry record (NCT05556512) — ClinicalTrials.gov
15. SYNERGY-OUTCOMES registry record (NCT07165028) — ClinicalTrials.gov
16. FDA approves Lilly’s Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes — Eli Lilly and Company, August 2026